Personalized Mobile Cognitive Behavioral Therapy Application
NCT05699525
Recruiting
This study aims to compare the effectiveness of a standard mobile iPhone cognitive behavioral therapy program to a personalized mobile iPhone cognitive behavioral therapy program that introduces new skills over a shorter period of time. Participants will use the Maya app for two days per week, at least 20 minutes per day, for six weeks. Assessments will include a weekly check in with a member of the research team, questionnaires, and optional magnetic resonance imaging (MRI) and electroencephalo... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
04/28/2025
Locations: Weill Cornell Medical College, New York, New York
Conditions: Anxiety Disorders and Symptoms, Depression, Bipolar Disorder, Symptoms
Register for Updates
CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease
NCT05718791
Recruiting
The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/28/2025
Locations: Henry Ford Health System, Detroit, Michigan
Conditions: GVHD,Acute
Register for Updates
Cold Agglutinin Disease Real World Evidence Registry
NCT05791708
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Alabama at Birmingham Site Number : 1230, Birmingham, Alabama +67 locations
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
Register for Updates
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
NCT05810025
Recruiting
Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several challenges. The purpose of this study is to assess how the integration of patient generated health data (PGHD) and EHR data can generate more accurate risk prediction models, advance personalized cancer prevention, improve digital access to health data in an equitable man... Read More
Gender:
FEMALE
Ages:
Between 35 years and 74 years
Trial Updated:
04/28/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Breast Cancer
Register for Updates
Age-dependent Effects of Smoked and Oral Delta-9-THC
NCT05865470
Recruiting
This study will assess the age-dependent effects of smoked and oral THC on abuse liability, intoxication, analgesia and impairment as a function of age.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/28/2025
Locations: UCLA Center for Cannabis and Cannabinoids, Los Angeles, California
Conditions: Pain, Abuse, Drug, Intoxication; Cannabinoids
Register for Updates
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT06003153
Recruiting
The goal of this research study is to evaluate the pathophysiologic mechanisms by which genetic variation impacts response to an FDA-approved medication commonly used to treat type 2 diabetes called oral semaglutide (Rybelsus) and to characterize the physiological response to a mixed meal tolerance test (MMTT) before and after a 14-day treatment with oral semaglutide. The investigators will do this by measuring factors in the blood, such as sugars, fats, metabolites, and proteins, after eating a... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/28/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Genetic Predisposition, Metabolic Diseases, Type 2 Diabetes
Register for Updates
Mindfulness Based Stress Reduction App
NCT06079840
Recruiting
African American caregivers of people living with HIV/AIDS (PLWHA) have unique needs because they are more likely to experience stressors related to intersecting sources of stigma, discrimination, and caregiving burdens specifically associated with caregiving for PLWHA. The proposed project will enhance and finalize Phase I app development and evaluate its effectiveness in a randomized controlled trial. The project has high public health significance because of its potential to provide an access... Read More
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/28/2025
Locations: Friends Research Institute, Baltimore, Maryland
Conditions: Stress Reduction
Register for Updates
Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
NCT06085729
Recruiting
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Prostate Cancer
Register for Updates
Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
NCT06088381
Recruiting
Patients with human papillomavirus (HPV)-related oropharyngeal cancer generally have favorable outcomes and how well they do depends on the specific details about the patient and their cancer. How well they do isn't as related to the kinds of treatment they get. However, there are significant side effects for the various types of treatments they may get. Because these patients generally have favorable outcomes no matter the kind of treatment, reducing side effects should be a priority when choos... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Maryland Proton Treatment Center, Baltimore, Maryland +4 locations
Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oropharynx Cancer, Oropharynx Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Register for Updates
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
NCT06120140
Recruiting
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (\>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. A substudy will enroll participants from Arms A and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Ironwood Cancer and Research Center, Chandler, Arizona +92 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843
Recruiting
The purpose of this study is to establish a safe and tolerable dose of BMS-986393 in combinations with alnuctamab, mezigdomide, and iberdomide in participants with relapsed and/or refractory multiple myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +18 locations
Conditions: Multiple Myeloma
Register for Updates
The Grief Navigation Trial: A Comparison of Two Interventions to Support Parents After Their Child's Unexpected or Traumatic Death
NCT06136260
Recruiting
Parents of children who die traumatically or unexpectedly from things like suicide or an overdose suffer from mental and physical health problems and can experience massive disruptions in their family life. For about half of these parents, the first, and sometimes only, interactions they have with the healthcare system when their child dies are with a medical examiner or coroner (hereafter 'ME'). But MEs have little to no training in helping grieving families, and there are no standards guiding... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/28/2025
Locations: Cook County Medical Examiner's Office, Chicago, Illinois +6 locations
Conditions: Bereavement
Register for Updates